Abstract 1649P
Background
Precision medicine for pancreatic cancer (PC) is one of the promising treatment strategies. However, only a few patients can receive genotype-matched treatments for the low detection rate of actionable genomic alterations, therefore the clinical utility of comprehensive genomic profiling (CGP) is still unknown. On the other hand, CGP gives us a lot of information such as prognosis, future eligibility for genotype-matched clinical trials, and it may affect physician’s treatment strategies. The present study was to investigate the contribution to prognosis of CGP, and its appropriate timing in the treatment of advanced PC.
Methods
This was a single-center, retrospective cohort study. Patients who were diagnosed as recurrent or metastatic PC with adenocarcinoma or adenosquamous carcinoma and underwent systemic chemotherapy between April 2018 and March 2022 were recruited. We reviewed the medical records and collected data of patient characteristics, survivals, and genomic information. We compared overall survival (OS) according to those who had received CGP (CGP group) or not (non-CGP group), and those who had performed CGP before or after initial chemotherapy.
Results
A total of 107 patients were eligible, in which 47 patients had received CGP. Patient characteristics were not statistically different between two groups except for age. OS was significantly longer in CGP group than non-CGP group (median, 29.7 vs 13.4 months; hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.30–0.89; P < 0.017). OS tended to be longer in patients who had received CGP before the initiation of systemic chemotherapy than those who had received CGP after initial chemotherapy (median, 40.1 vs 24.0 months; HR, 0.29; 95% CI, 0.085–1.02; P=0.054). Actionable genomic alterations were detected in 16 patients (34.0%), whereas genotype-matched treatments were implemented for five patients (10.6%).
Conclusions
In the present study, OS was prolonged in patients who had undergone CGP irrespective of implementation of genotype-matched treatments, suggesting that CGP could help physicians to select the optimal treatment strategies for advanced PC in clinical practice. Given the extremely poor prognosis of the disease, earlier timing of CGP is considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1701P - Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland
Presenter: Miquel Serra-Burriel
Session: Poster session 22
1702P - Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022
Presenter: Jeroen W. G. Derksen
Session: Poster session 22
1703P - Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022
Presenter: Ariadna Tibau
Session: Poster session 22
1704P - Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time
Presenter: Molto Consolacion
Session: Poster session 22
1705P - Therapeutic value of first vs supplemental indications of drugs in the US and Europe (2011-2020): Retrospective cohort study
Presenter: Kerstin Vokinger
Session: Poster session 22